Background Major adverse cardiovascular events (MACE) are increasingly used as
composite outcomes in randomized controlled trials (RCTs) and observational studies …

Background Metformin is the most widely prescribed drug to lower glucose and has a
definitive effect on the cardiovascular system. The goal of this systematic review and meta …

With an increasing global burden of coronary artery disease (CAD), early detection and
timely management of risk factors are crucial to reduce morbidity and mortality in such …

Background Guidelines have classified patients with acute coronary syndrome (ACS) and
diabetes as a special population, with specific sections presented for the management of …

Abstract Type 2 diabetes (T2D) has become a global epidemic. Although several drugs are
available to manage T2D, problems associated with person-to-person variability in drug …

The incidence of diabetes has increased globally in recent years and figures of diabetic
patients were estimated to rise up to 642 million by 2040. The disorder is accompanied with …

α-Glucosidase and α-amylase are the two main glycosidases that participate in the
metabolism of carbohydrates. Inhibitors of these two enzymes are considered an important …

Highlights•Report reveals the pathological cascade in metabolic disorders.•Molecular
signalling explain how gut bacteria leads to diabesity.•Report explains the vicious circle of …

Background The potential for PPAR agonists to positively affect risk of cardiovascular
disease in patients with type 2 diabetes (T2DM) is of persistent attention. The PRESS XII …

The gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes
mellitus (T2DM). In this study, we investigated the synergistic potential of combining the …